Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

440.66 +2.01 (+0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
61 62 Next >
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
These biotech stocks with promising pipelines are showing some major promise and growth potential for the new year. 
Via InvestorPlace
Why Vertex Stock Is Soaring Today
The drugmaker's non-opioid painkiller is showing promise in a select set of patients. 
Via The Motley Fool
Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700... 
Via Benzinga
Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday?
Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is a Leading Gainer in 12/13 Morning Trading
Via Investor Brand Network
Vertex's Non-Opioid Diabetes Associated Nerve Pain Treatment Candidate Aces Mid-Stage Trial
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) released results from its Phase 2 dose-ranging study of VX-548 (non-opioid pain medicine) for diabetic peripheral neuropathy, a type of nerve damage  
Via Benzinga
Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment
The company tested an alternative to opioids and NSAIDs in patients with diabetic peripheral neuropathy. 
Via Investor's Business Daily
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
The overall sector may be struggling after COVID, but there's still great potential in these three biotech stocks. 
Via InvestorPlace
Exposures COVID-19
1 Biotech Stock That Could Be the Next Amgen
The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen. 
Via The Motley Fool
Vertex Stock Flashes Bullish Signal On Phase 2 Results For Opioid Alternative
Vertex stock spiked early Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug. 
Via Investor's Business Daily
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy right now. 
Via The Motley Fool
The Latest Analyst Ratings for Vertex Pharmaceuticals
Via Benzinga
Forget the "Magnificent Seven": Buy This Stock Instead
It's hard to go wrong with this high-flying drugmaker. 
Via The Motley Fool
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR. 
Via InvestorPlace
Exposures Product Safety
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. 
Via Investor's Business Daily
Exposures Product Safety
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Why CRISPR Stock Keeps Falling
CRISPR just scored its first FDA victory -- but profits remain years away. 
Via The Motley Fool
Exposures Product Safety
Bull Of The Day: Crispr Therapeutics
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
These stocks could be just the ticket for investors seeking strong growth. 
Via The Motley Fool
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
The big biotech's shares have been on the rise this year. 
Via The Motley Fool
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead. 
Via The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
Exposures Product Safety
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Treasury yields and crude oil came off multimonth lows on Friday's jobs report. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Crispr Stock Rises Ahead Of Expected FDA Approval Of Gene-Editing Treatment
Crispr stock rose in early trades on Friday ahead of the FDA's expected approval of a groundbreaking gene-editing treatment. 
Via Investor's Business Daily
Exposures Product Safety
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
The timing of the cuts is setting off alarm bells, but the situation is under control. 
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.